Transforming the discovery of novel GPCR-targeted therapies

The Himalayas are the result of an ongoing, 50 million year-long collision between the Indian and Eurasian Tectonic Plates. As tectonic movements on the Earth’s surface affect the planet, GPCR interactions represent surface events that have profound effects on cell responses.

About Us

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). With our proprietary GEODe™ platform, we are targeting the most difficult, previously undruggable receptors in the class, aiming to unlock their therapeutic utility to develop new treatments for a broad range of patients with important unmet needs.
Leadership
Alise Reicin, M.D.

President and CEO, Director

Christian Cortis, Ph.D.
Chief Operating Officer

Anthony Muslin, M.D.

Chief Development Officer

Marc Schwabish, Ph.D.

Chief Business Officer

Peter McNamara, Ph.D.

Senior Vice President,
Head of Research

Board of Directors
Terry Mcguire
Chair, Board of Directors, Tectonic Therapeutic and Partner, Polaris Partners

Timothy A. Springer, Ph.D.

Co-Founder, Tectonic Therapeutic, Latham Family Professor, Harvard Medical School and Professor of Medicine, Children’s Hospital Boston
Stefan Vitorovic
Co-Founder and Managing Director, Vida Ventures
Alise Reicin, M.D.
President and CEO, Tectonic Therapeutic
Andrew Kruse, Ph.D.
Co-Founder and Advisor, Tectonic Therapeutic and Professor, Harvard Medical School
Praveen Tipirneni, M.D.
President and CEO, Morphic Therapeutic
Investors

Our Science

G protein-coupled receptors (GPCRs) are central to human biology and are the target of ~1/3 of all approved drugs. GPCRs remain a large untapped opportunity as many receptors remain unexplored or are undruggable by small molecules. A biologic approach will address major challenges by increasing specificity and by facilitating the targeting of GPCRs whose natural ligands are peptides or proteins.

Tectonic has unparalleled expertise in the biochemistry and biophysics of GPCRs, and the knowledge and experience to translate basic research in this field into novel therapies. Our GEODe™ platform overcomes the challenges encountered to date in GPCR biologic discovery campaigns, enabling the advancement of novel GPCR-targeting therapies.

News & Media

Tectonic Therapeutic Appoints Marcella Ruddy, MD as Chief Medical Officer
July 22, 2021
Tectonic Therapeutic, a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Dr. Marcella (“Marcie”) Ruddy, MD has been appointed Chief Medical Officer.
Tectonic Therapeutic Appoints Peter McNamara, PhD Senior Vice President, Head of Research
May 27, 2021
Tectonic Therapeutic, a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Peter McNamara, PhD has been appointed Senior Vice President, Head of Research.
Tectonic Therapeutic Launches with $80 Million Series A Financing to Transform the Discovery of Novel G-Protein Coupled Receptor (GPCR)-Targeted Therapies

April 15, 2021

Tectonic Therapeutic, a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that it has raised $80 million in a Series A financing.

Congratulations to the Winners of the 2020 Harvard President’s Innovation Challenge

May 26, 2020
Tectonic Therapeutic is the recipient of a grand-prize of $75,000 in the 2020 Harvard President’s Innovation Challenge for transforming the discovery of novel drugs addressing targets in the G-protein-coupled receptor (GPCR) family.

Careers

Open Positions
Director of Cell Biology

Head of Laboratory Operations

Our Culture

At Tectonic we are motivated by a “speak-up culture” where divergent perspectives are shared openly, respectfully, and fearlessly. We understand that we can learn from both triumphs and setbacks and that breakthroughs are often the result of the most unexpected insights.

We believe a shared commitment to excellence and creativity is what makes meaningful scientific and medical advances possible. We work hard yet find time to laugh together as we drive toward achieving a common goal-improving human health. We collaborate because we recognize the urgent need for new therapies and that teams score more goals than individuals. We value diversity both in who we are and in how we think because the more perspectives we bring to a challenge, the more likely we are to succeed.

Tectonic – a place to grow and succeed together.

Contact Us

Tectonic Therapeutic
Copyright © 2021 Tectonic Therapeutic